EU/3/08/529

Table of contents

About

On 4 February 2008, orphan designation EU/3/08/529 was granted by the European Commission to Morvus Technology Limited, United Kingdom, for tretazicar for the treatment of visceral leishmaniasis.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
tretazicar
Disease / condition
Treatment of visceral leishmaniasis
Date of decision
04/02/2008
Outcome
Positive
Orphan decision number
EU/3/08/529

Sponsor's contact details

Morvus Technology Limited
Llanvetherine Court
Llanvetherine
Abergavenny
NP7 8NL
United Kingdom
Tel. + 44 (0)1558 668111
E-mail: info@morvus.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating